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In our preceding paper,1} we have reported on the synthesis, the antibacterial activity and the oral absorbability of 7jS-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]cephalosporins with 1,2,3-triazole in the C-3 side chain. Amongthese compounds 3-(l,2,3-triazol-4-yl)thiomethylthio-3-cephem-4-carboxylic acid (1) was selected for further evaluation, which showed well-balanced good antibacterial activity against Gram-positive and Gram-negative bacteria and attained high plasma level after oral administration in mice and monkeys. That study has also given us the finding that the spacer moiety between C-3 of the cephem nucleus and C-4' of 1,2,3-triazole was a factor affecting the oral absorbability; good oral absorbability was obtained when the spacer moiety was a three-atom chain, especially a thiomethylthio chain. In this paper, we wish to report the synthesis of 2 and the effects of the alteration of the heteroaromatic ring in the C-3 side chain of 1 on antibacterial activity and oral absorbability in mice.
Chemistry
Scheme 1 outlines two methods for the synthesis of the 3-heterocyclicthiomethylthiocephalosporins (2). The preparation of2a~2d, 2h and 2n was carried out by method A and that of2e~2g and 2i~2m by methodB.
Method A, which had also been used for the synthesis of compound1, involves the coupling of 3-methanesulfonyloxycephalosporin1) (3) with sodium thiolate, prepared in situ by methanolysis of the corresponding heterocyclicthiomethyl thioacetate, to give 3-substituted compound 4. This method gave compound4 in one step but in some cases could not give 4, even in a poor yield, probably due to the BH =diphenylmethyl, Tr=triphenylmethyl, mCPBA=m-chloroperbenzoic acid, HMPA= hexamethylphosphoric triamide. FEB. 1993 instability of the intermediate sodium thiolate.2) An alternative procedure (method B), which does not include the thiolate intermediate, was suited for the synthesis of 4 in such cases. MethodB is more general than method A and also applicable to the compoundsprepared by method A. In method B, 3 was oxidized with ra-chloroperbenzoic acid (raCPBA) and treated successively with sodium hydrosulfide and silver nitrate to yield silver salt (5) , which was reacted with heterocyclicthiomethyl iodide in hexamethylphosphoric triamide (HMPA) to afford 3-substituted sulfoxide (6). 3-(4-Methyl-l ,2,4-triazol-3-yl)thiomethylthiocephalosporin (6g) was prepared by modified method B. As shown in Scheme 2, 5 was reacted with [l-trityl-l,2,4-triazol-3-yl] thiomethyl iodide (7) to give 3-substituted compound (8). The trityl group was removed with p-toluenesulfonic acid to yield compound 9, which was methylated with methyl triflate to give compound 6g. The reduction of sulfoxide (6) with phosphorus trichloride (PC13) gave compound 4.
The preparation ofthioacetates and iodides used here was shown in Scheme3. Each isomers (12~14; 18, 19; 28, 29) were assigned by means of NOEor 13C NMRstudy,3) or by comparison with authentic samples.
Finally the deprotection of 4 by the conventional method using aluminum chloride (A1C13) produced the desired cephalosporin derivatives (2a~2n).
Antibacterial Activity and Oral Absorption The in vitro antibacterial activity of the new cephalosporins (2) against selected Gram-positive and Gram-negative bacteria is shown in Table 1 . Their plasma levels and urinary recovery after oral administration (40 mg/kg) to mice are summarized in Table 2 . Also shown is their relative bioavailability which was calculated according to the following equation: urinary recovery after po dosage relative bioavailability (%) =-: x 100 urinary recovery after sc dosage and we used this bioavailability and plasma levels as measures of gastrointestinal absorption. Most of the new cephalosporins exhibited potent activity against the Gram-positive and Gram-negative bacteria except Pseudomonas aeruginosa ATCC25619, irrespective of the heteroaromatic ring. Derivatives with thiadiazole in the C-3 side chain (2k~2m) showedhigher activity against a wide range of bacteria than the other cephalosporins prepared, including compound 1. Compounds2k and 21 showed the most potent activity against Gram-positive bacteria including Staphylococcus aureus SR3131 (MRSA) among all of the compoundstested. Compounds (2b and 2n) having 2-methyl-l,2,3-triazole or pyridine in the C-3 side chain, showed good Mice: ICR-strain, 6-week-old male, n = 5. The urinary samples were collected over 2 hours and the relative bioavailability was calculated from the urinary recovery over 2 hours. or 2d), but other TV-methylated derivatives (2a, 2c or 2f, 2g) showed lower oral absorbability.
Experimental
MPwas determined with a Yanagimoto micro melting point apparatus and uncorrected. IR spectra were taken on a Jasco IR-700 spectrometer. *H NMR spectra were recorded at 200MHz on a Varian VXR-200NMRspectrometer using TMSor sodium 2,2-dimethyl-2-silapentan-5-sulfonate (in D2O) as an internal standard. Mass spectra (EI-MS) was measured on a Hitachi M-68 mass spectrometer. The following abbreviations are used: s, singlet; d, doublet; m, multiplet; br, broad; ABq, ABquartet. All reactions under anhydrous conditions were carried out using anhydrous solvents dried over Molecular Sieves type 4A in a nitrogen atmosphere.
Determination of Antibacterial Activity
All the in vitro antibacterial activities are given as MICin fig/ml required to prevent growth of the bacterial culture. MICs were determined by the serial agar dilution method (Sensitivity Disk Agar-N) after incubation at 37°C for 18~20 hours with an inoculum size of about 106cells/ml.
Oral Absorption Study
Male ICR-strain mice aged 6 weeks weighing 24~30 g were used in groups of 5. The antibiotics were given to mice orally in a single dose of 40mg/kg or subcutaneously in 20mg/kg as a solution in dilute aqueous sodium bicarbonate. Plasma samples were collected at 0.25 and 2 hours respectively after dosing and urine specimens were collected over a period of 2 hours after dosing. The concentrations of the test compounds were determined by the Band Culture method6) using Escherichia coli 7431 as a test organism and Trypto-soy agar as the test medium.
(4a) A solution of 12 (392mg, 1.93mmol) in THF (2ml) and DMF(6ml) was cooled to -78°C and treated with a solution of sodium methoxide in MeOH(1.28n, 1.33ml). After the mixture was stirred at -78°C for 15 minutes, a solution of 3 (1.50g, 1.54mmol) in DMF(5ml) was added dropwise to the above mixture. After being stirred at the same temperature for 50 minutes, the mixture was neutralized with 10% HC1, diluted with water and extracted with EtOAc. The extract was washed with brine four times, dried over anhydrous Na2SO4 and evaporated. The resulting residue was purified by column chromatography on silica gel (eluent; toluene -EtOAc, 3 : 2) to yield 1.43 g (90%) of4a as colorless froth.
Compounds 4b~4d, 4h and 4n were similarly prepared from 3 with corresponding thioacetates (13, 14, 16, 27 and 44) according to the procedure described for 4a. The spectral data of4a~4d, 4h and 4n are listed in Table 3 . A solution of this sulfoxide (18.6g, 18.8mmol) in DMF(150ml) was cooled to -30°C and treated with sodium hydrosulflde (70%) (3.77 g, 47.1 mmol). After the mixture was stirred at -20~-30°C for 1.5 hours, 10%HC1 (15ml) was added to the mixture. This mixture was diluted with water, extracted with EtOAc, washed with brine, dried over anhydrous Na2SO4and evaporated. The residue was dissolved in toluene and concentrated to yield 17.6 g (93%) of diphenylmethyl 7j5-[(2T)"2-(2-rerr-butoxycarbonylaminothiazol-4-yl)-2-triphenylmethoxyiminoacetamido] -3-mercapto-3-cephem- A solution of this mercaptan (92%) (17.5g, 17.5mmol) in THF(120ml) was treated with an aqueous solution of silver nitrate (3.26g, 19.2mmol in 16ml of water) under ice-cooling. After being stirred at ice-bath temperature for 30 minutes, the mixture was diluted with methylene chloride and water. The organic layer was separated, washed with water, dried over anhydrous Na2SO4and evaporated to give 19.7g of dark yellow froth: Calculated purity of 5 was 92%. amido]-3-( 1 -methyl-1 H-1 ,2,4-triazol-5-yl)thiomethylthio-3-cephem-4-carboxylate 1 -Oxide (6e) A solution of23 (1.47g) in HMPA(3ml) was added to a solution of5 (92%) (3.37g, 3.00mmol) in HMPA(20ml). After the mixture was stirred at room temperature for 3 hours, brine and EtOAc were added to the mixture and the resulting precipitate was filtered off. The organic layer was separated, washed with brine six times, dried over anhydrous Na2SO4and evaporated. The resulting residue was purified by column chromatography on silica gel (eluent; toluene-EtOAc, 1 : 1) to yield 1.76g (56%) of 6e as pale brown froth.
Compounds 6f, 6i~6m and 8 were similarly prepared from 5 with corresponding iodides (7, 22, 32, 33, 36, 41 and 42) according to the procedure described for 6e. The spectral data of6e, 6f, 6i~6m and 8 are listed in Table 4 .
A solution of 8 (ll.3g, 8.83mmol) in acetone (60ml) was treated with /7-toluenesulfonic acid monohydrate (1.68 g, 8.83 mmol) under ice-cooling. After the mixture was stirred at room temperature for 4 hours, 5%aq NaHCO3 and EtOAcwere added to the mixture. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4and evaporated. The resulting residue was purified by column chromatography on silica gel (eluent; toluene-EtOAc, 1 : 1->1 :2) to yield 2.84g (31%) of 9 as brown A solution of 9 (2.71 g, 2.61 mmol) in THF (50ml) was treated with 1.0m THF solution of lithium hexamethyldisilazane (2.9ml) at -78°C. After the mixture was stirred at the same temperature for a few minutes, methyl triflate (0.33ml, 2.92mmol) was added to the mixture, which was stirred at -78°C for 30minutes. The reaction was quenched by 10% HC1(2.1 ml). The mixture was diluted with water and extracted with EtOAc. The extract was washed with brine, dried over anhydrous Na2SO4and evaporated. The resulting residue was purified by column chromatography on silica gel (eluent; EtOAc) to yield 730 mg (27%) of 6g as pale brown froth. The spectral data of 6g are listed in Table 4 .
Diphenylmethyl 7j&-[(Z)-2-(2-^rr-Butoxycarbonylaminothiazol-4-yl)-2-triphenylmethoxyiminoacetamido] -3-( 1 -methyl-1 H-1 ,2,4-triazol-5-yl)thiomethylthio-3-cephem-4-carboxylate (4e) A solution of6e (1.73 g, 1.64mmol) in DMF(15 ml) was treated with phosphorus trichloride (0.41 ml, 4.08 mmol) at -20°C. After being stirred at the same temperature for 20 minutes, the mixture was poured into a cold mixture of 5% aq NaHCO3 (ca. 42ml) and EtOAc. The organic layer was separated, washed with brine four times, dried over anhydrous Na2SO4and evaporated. The resulting residue was purified by column chromatography on silica gel (eluent: toluene -EtOAc, 2 : 1) to yield 1.60 g (94%) of4e as brown froth.
Compounds 4f, 4g and 4i~4m were similarly prepared according to the procedure described for 4e. The spectral data of4e~4g and 4i~4m are listed in Table 3 . solution of A1C13 (1.43g, 10.8mmol) in anisole (5ml) was added dropwise to a solution of 4b (1.39g, 1.34mmol) in anisole (5ml) and nitromethane (20ml) at -30~-40°C. After the mixture was stirred at the same temperature for an hour, llml of In HC1, water and EtOAcwere added to the mixture. The aqueous layer was separated and the organic layer was re-extracted with water. The combined aqueous layer was chromatographed on an Diaion HP-20 column (eluent; methanol-water, 4 : 1). After the concentration, the resulting precipitate was collected by filtration, washed with EtOAc and dried in vacuo to give 534mg (75%) of 2b as pale yellow powder.
The spectral data of various derivatives 2a~2n are listed in Table 5 .
l i/-l ,2,3-Triazol-4-ylthiomethyl Thioacetate (ll) A suspension of 10 (purchased from Dynamit Nobel Aktiengesellschaft) (38.0g, 0.31 mol) in DMF (150ml) was treated with chloromethyl thioacetate7) (37.4g, 0.30mol) at -20°C. After being stirred at room temperature for 2 hours, the mixture was poured into water, extracted with EtOAc. The organic layer was washed with brine four times, dried over anhydrous Na2SO4and evaporated. The resulting crystalline residue was washed with hexane and dried in vacuo. Recrystallization from ether gave 38.9 g (69%) of ll as white crystals: MP 88~89°C; *H NMR (CDC13) C 31.65, H 3.69, N 22.44, S 33.62. l -Methyl-li/-l ,2,3-triazol-4-ylthiomethyl Thioacetate (12), FEB. 1993 Thioacetate (13) and 1-Methyl-l//-l ,2,3-triazoI-5-ylthiomethyl Thioacetate (14) Methylation of ll with Diazomethane A solution of ll (5.80 g, 30.7 mmol) in THF (50 ml) was treated with an ether solution ofdiazomethane under ice-cooling. After being stirred at the same temperature for an hour, the mixture was concentrated.
The resulting residue was purified by Lobar column chromatography (eluent; toluene-EtOAc, 10: 1-*1 : 1->1 :2) to afford 306mg (5%) of12 as white crystals, 3.77g (61%) of 13 as a colorless oil and 429mg (7%) of 14 as white crystals.
Methylation of ll with Methyl Triflate
A solution of ll (6.00g, 31.8mmol) in THF (30ml) was treated with 1.0m THF solution of lithium hexamethyldisilazane (35 ml) at -78°C. A few minutes later, methyl triflate (4.0 ml, 35.3 mmol) was added to the mixture. After the mixture was stirred at -78°C for 2 hours, 26ml of 10%HC1was added to the mixture, which was diluted with water, extracted with EtOAc, washed with brine, dried over anhydrous Na2SO4and evaporated. The resulting residue was purified by Lobar column chromatography (eluent; toluene-EtOAc, 1 :2) to afford 884mg (14%) of 12, 175mg (3%) of 13 and 2.22g (34%) of 14. l -Triphenylmethyll i/-l ,2,4-triazol-3-ylthiomethyl Thioacetate (16) A solution of 15 (2.23g, 22.1 mmol) in DMF(30ml) was treated with sodium hydride (60% in oil) (840mg, 21.0mmol) and stirred at room temperature for 10 minutes. After the mixture was cooled to -60°C, a solution of chloromethyl thioacetate7) (2.50g, 20.1 mmol) in DMF(5ml) was added to the reaction mixture. After the mixture was stirred at -50--60°C for 20 minutes, trityl chloride (6.70g, 24.0mmol) and pyridine (1.94ml, 24.0mmol) were added to the mixture, which was stirred at ice-bath temperature for 28 hours. The reaction mixture was diluted with water and extracted with EtOAc. The extract was washed with brine four times, dried over anhydrous Na2SO4and evaporated. The resulting residue was purified by column chromatography on silica gel (eluent; toluene -EtOAc, 20 : 1) and crystallized from ether to yield 3.37g (39%) of 16 as white crystals: MP 124-125°C; XH NMR(CDC13) S 7.90 (1H, s), 7.4-7.3 (9H, m), 7.2-7.1 (6H, m) 3-i-Methoxybenzylthio-1H-1 ,2,4-triazole (17) To a solution of 15 (10.1 g O.lOmol) and /?-methoxybenzyl chloride (17.2g, 0.ll moi) in methylene chloride (50ml), I n aq NaOH (105ml) and tetra-«-butylammonium bromide (750mg, 233mmol) were added. After the mixture was stirred at room temperature for 16 hours, the organic layer was separated, washed with brine, dried over anhydrous Na2SO4and evaporated. The residue was crystallized from 3-Chloromethylthio-1 -methyl-1 H-1 ,2,4-triazole (20) A solution of 18 (3.55 g, 15.1 mmol) in methylene chloride (30ml) and methanol (30ml) was treated with silver perchlorate (90%) (4.17 g, 18.1 mmol). After being stirred at room temperature for 1.5 hours, the mixture was diluted with methanol. The precipitate was collected by nitration and dried in vacuo. This white solid was suspended in DMF(30ml), and bromochloromethane (30ml) and lithium chloride (98%) (1.96g, 45.3mmol) were added to the suspension, which was stirred at room temperature for 20 hours. Brine and EtOAcwere added to the reaction mixture and filtered. The organic layer was separated, washed with brine three times, dried over anhydrous Na2SO4and evaporated. The resulting residue was purified by column chromatography on silica gel (eluent; toluene-EtOAc, 2: 1) to yield 1.05g (43%) of 20 as a 3-Iodomethylthio-1 -methyl-1 H-1 ,2,4-triazole (22) A solution of 20 (981 mg, 6.00mmol) in acetone (10ml) was treated with sodium iodide (1.78g, 12.0mmol) and stirred at 50°C for 3 hours. The reaction mixture was diluted with water and extracted with EtOAc. The extract was washed with water, dried over anhydrous Na2SO4and evaporated to afford 1.50g of crude 22 as a yellow oil. This oil was employed for the reaction with silver salt 5 without purification:
XH NMR(CDC13) S 8.07 (1H, s), 4.75 (2H, s), 3.94 (3H, s).
5-Iodomethylthio-1 -methyl-1 H-1 ,2,4-triazole
Compound23 was prepared from 21 as described for the preparation of 22: *H NMR(CDC13) 3-Chloromethythio-1 -triphenylmethyl-1 H-1 ,2,4-triazole (24) A solution of 15 (10.0g, 99.0mmol) in DMF(100ml) was treated with sodium hydride (60% in oil) (3.96 g,99.0 mmol)under ice-cooling. After the mixture was stirred at the same temperature for 10 minutes, bromochloromethane (100ml) was added to the mixture, which was stirred at room temperature for 15
